PremiumCompany AnnouncementsVir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress Vir Biotechnology: Strong Financials and Promising Pipeline Justify Buy Rating Vir Biotechnology: Strong Financial Health and Promising Clinical Progress Justify Buy Rating PremiumRatingsVir Biotechnology Poised for Growth: Buy Rating Reiterated Amid Clinical and Financial Advancements Vir Biotechnology price target raised to $31 from $26 at Barclays Vir Biotechnology’s Transformative Year: Earnings Call Insights PremiumRatingsVir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating Vir Biotechnology reports Q4 EPS (76c), consensus (87c) VIR Earnings this Week: How Will it Perform? 
